Cystitis, Interstitial

5
Pipeline Programs
4
Companies
7
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
3
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

UP
CIMZIAApproved
certolizumab pegol
UCB Pharma
Tumor Necrosis Factor Blocker [EPC]injection2008
U
MYRBETRIQApproved
mirabegron
Unknown Company
beta3-Adrenergic Agonist [EPC]oral2012
U
MYRBETRIQ GRANULESApproved
mirabegron
Unknown Company
beta3-Adrenergic Agonist [EPC]oral2021

Competitive Landscape

3 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
1 program
1
1
Certolizumab pegolPhase 31 trial
Active Trials
NCT02497976Completed42Est. Jul 2017
Astellas
AstellasChina - Shenyang
1 program
1
MirabegronPhase 31 trial
Active Trials
NCT02787083Terminated9Est. Jul 2019
Pfizer
PfizerNEW YORK, NY
1 program
ERB-041N/A5 trials
Active Trials
NCT00434187Completed24Est. Oct 2006
NCT00275379Withdrawn0
NCT00316459Completed64
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasMirabegron
UCB PharmaCertolizumab pegol
PfizerERB-041
PfizerERB-041
PfizerERB-041
PfizerERB-041
PfizerERB-041

Clinical Trials (7)

Total enrollment: 361 patients across 7 trials

NCT02787083AstellasMirabegron

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis

Start: Aug 2016Est. completion: Jul 20199 patients
Phase 3Terminated
NCT02497976UCB PharmaCertolizumab pegol

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Start: Dec 2015Est. completion: Jul 201742 patients
Phase 3Completed
NCT00110487PfizerERB-041

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Start: Jan 2005Est. completion: Dec 2006200 patients
Phase 2Completed
NCT00434187PfizerERB-041

Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

Start: Aug 2006Est. completion: Oct 200624 patients
Phase 1Completed
NCT00316459PfizerERB-041

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

Start: May 200664 patients
Phase 1Completed
NCT00245947PfizerERB-041

Study Evaluating ERB-041 in Active Crohn's Disease

Start: Apr 2004Est. completion: Apr 200522 patients
Phase 1Completed
NCT00275379PfizerERB-041

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

Start: Aug 20060
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space